SEC filings and other documents

Positive cash flow and robust glaucoma growth highlight Q2, despite retina-driven revenue decline.

Operational efficiency and clinical innovation drive growth and recurring revenue expansion.

Innovative laser solutions and operational efficiencies drive growth and profitability in eye care.

Profitability achieved in Q4 2025, with strong growth in retina and glaucoma laser markets.

Q1 revenue flat at $11.8M; G6 probe growth offsets Retina headwinds; 2026 guidance reaffirmed.

Q4 and full-year 2025 saw strong revenue growth, margin pressure, and a return to positive cash flow.

Turnaround strategy drives growth, margin expansion, and innovation in laser-based eye care.

Revenue up 8% year-over-year, with improved EBITDA and cost reductions despite a one-time charge.

Q2 2025 delivered revenue growth, cost reductions, and positive adjusted EBITDA, led by strong retina sales.

Q1 2025 saw revenue growth, positive adjusted EBITDA, and strengthened financial health.

Cost cuts, revenue growth, and a $10M investment position the business for profitable expansion.

Revenue and margins improved in Q4 2024, with strategic investment fueling future growth.

Cost reductions and new reimbursement rules set the stage for Q4 profitability and growth.

Revenue and margins declined, but new financing supports near-term liquidity amid ongoing risks.